To determine if FAC is also affecting P-gp degradation, MBECs could be treated with a proteasome inhibitor (e.g., MG132) in the presence and absence of FAC, and assess P-gp abundance over time, as has been reported in human colorectal cancer cells previously [54]. Here, PGP is linked to colorectal cancer.